Filing summary
Entity discrepancy: The request identifies GRI Bio, Inc., but the supplied Form 10-Q is for Vallon Pharmaceuticals, Inc. (Nasdaq: VLON). This summary reflects Vallon’s filing, for the quarter ended September 30, 2022, filed November 3, 2022.
Business context and reporting period
Vallon was a clinical-stage biopharmaceutical company developing abuse-deterrent medicines for central nervous system disorders. Its lead candidate, ADAIR, is an abuse-deterrent dextroamphetamine formulation; ADMIR is an abuse-deterrent methylphenidate formulation. Vallon had no approved products and had not generated product-sale revenue.
Financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | No reported revenue | No reported revenue | No reported revenue | No reported revenue |
| Research and development | $(18,000) | $215,000 | $1.529 million | $3.189 million |
| General and administrative | $1.422 million | $1.038 million | $4.014 million | $2.976 million |
| Total operating expenses | $1.404 million | $1.253 million | $5.543 million | $6.165 million |
| Net loss | $1.033 million | $1.257 million | $5.441 million | $6.207 million |
| Net loss per share | $0.09 | $0.18 | $0.59 | $0.96 |
The Q3 R&D credit reflects, in part, a reversal of stock-based compensation. Q3 results also included a $757,000 gain from the change in warrant fair value and a $388,000 loss on warrant conversion.
At September 30, 2022, cash and cash equivalents were $4.732 million and available-for-sale marketable securities were $419,000, totaling approximately $5.151 million. Current assets were $5.569 million, current liabilities $2.110 million, and stockholders’ equity $3.459 million. The balance sheet reported a $225,000 warrant liability and no conventional borrowing balance. Nine-month operating cash use was $5.764 million; investing activities provided $3.362 million, primarily from net sales of marketable securities; financing activities provided $3.432 million, principally from the May offering. Cash increased $1.030 million to $4.732 million.
Material changes and notable developments
- In March 2022, Vallon reported that the ADAIR SEAL study failed its primary endpoint, Emax Drug Liking. It said the study met secondary pharmacodynamic endpoints, including Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours.
- Nine-month R&D expense fell $1.660 million year over year, mainly due to lower ADAIR development, personnel, and consulting costs. G&A rose $1.038 million, primarily from strategic-alternatives advisory and related expenses.
- A May 2022 registered direct offering sold 3.7 million shares at $1.0632 per share and issued warrants to buy 3.7 million shares at $0.9382. The company reported approximately $3.9 million gross proceeds and approximately $3.4 million net financing cash proceeds for the nine-month period.
- Following a warrant amendment, 2.22 million warrants were cashlessly exercised in August, resulting in issuance of 2.22 million shares. As of September 30, 1.48 million May 2022 warrants remained outstanding, in addition to 112,500 underwriters’ warrants. Shares outstanding rose to 12,732,836 from 6,812,836 at year-end 2021.
Outlook, risks, and contingencies
Management was assessing the future of ADAIR and ADMIR and had engaged Ladenburg Thalmann to explore strategic alternatives, potentially including a merger, business combination, investment, or asset sale, purchase, or license. The company was streamlining operations to preserve cash and expected to reduce R&D spending, while G&A could rise with strategic-review costs. No transaction or development plan was assured.
The filing states there is substantial doubt about Vallon’s ability to continue as a going concern. Management said additional financing may be needed; unavailable or unfavorable financing could force delays, reductions, or termination of development, or the sale or licensing of assets. If no strategic transaction is completed, the board could consider dissolution and liquidation, and stockholders could lose some or all of their investment. Other stated risks include the failed ADAIR primary endpoint, dependence on key employees, dilution, volatile share price, and uncertainty from COVID-19. Vallon reported no material legal proceedings and no material changes to previously disclosed risk factors other than those described in the filing.
Key facts for investors to verify
- Confirm the intended issuer: the supplied filing is Vallon Pharmaceuticals, not GRI Bio.
- Check subsequent disclosures for the status and outcome of the strategic-alternatives review and any decision on ADAIR, ADMIR, or liquidation.
- Assess cash use and financing needs against the reported $5.151 million of cash, cash equivalents, and marketable securities and the going-concern warning.
- Review the warrant amendment, remaining warrant overhang, and share-count changes for potential dilution and accounting effects.
- Verify any later clinical, regulatory, partnership, or licensing developments; the filing gives no clear operating runway estimate or specific forward financial guidance.